Plasma renin activity as a marker for predicting the antihypertensive effect of switching to sacubitril/valsartan in treated hypertensive patients: Usefulness in daily clinical practice.
angiotensin receptor–neprilysin inhibitor
blood pressure lowering
brain natriuretic peptide
plasma renin activity
Journal
Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
revised:
10
08
2024
received:
07
05
2024
accepted:
26
08
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
aheadofprint
Résumé
The authors investigated the antihypertensive effect of sacubitril/valsartan (Sac/Val) when switching from other drugs and assessed whether brain natriuretic peptide (BNP) or plasma renin activity (PRA) before drug switching was a predictor of blood pressure lowering after switching to Sac/Val. In 92 patients with treated hypertension, clinic blood pressure, plasma BNP, and PRA were examined before and after switching to Sac/Val. Clinic systolic and diastolic blood pressures significantly decreased after drug switching to Sac/Val (p < .0001, respectively). The level before drug switching of BNP had no correlation with the change in systolic blood pressure (Δ-SBP) before and after switching to Sac/Val, but that of PRA was significantly correlated with Δ-SBP (r = .3807, p = .0002). A multiple regression analysis revealed that PRA before drug switching was an independent determinant of Δ-SBP. Our findings suggest that low PRA may become a useful marker to predict the antihypertensive effect of switching to Sac/Val in treated hypertensive patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
Références
Imamura T, Kinugawa K. Implication of sacubitril/valsartan on N‐terminal pro B‐type natriuretic peptide levels in hypertensive patients. Ann Palliat Med. 2022;11:2856‐2561.
Mitsuno R, Uchiyama K, Nakayama T, et al. Comparison of the effects of angiotensin receptor‐neprilysin inhibitors and thiazide diuretic/renin‐angiotensin system inhibitor combination therapy in hypertensive patients: a retrospective cohort study. J Hum Hypertens. 2023;37:1049‐1055.
Lin DS, Wang TD, Buranakitjaroen P, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe. J Clin Hypertens. 2021;23:556‐567.
Yamamoto K, Rakugi H. Angiotensin receptor‐neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Res. 2021;44:1239‐1250.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double‐blind, multicenter study. Hypertens Res. 2022;45:824‐833.
Wu HX, Liu KK, Li BN, Liu S, Jin JC. Efficacy and safety of sacubitril/valsartan in the treatment of middle‐aged and elderly patients with hypertension: a systematic review and meta‐analysis of randomized controlled trials. Ann Palliat Med. 2022;11:1811‐1825.
Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Twenty‐four‐hour blood pressure‐lowering efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension based on nocturnal blood pressure dipping status: a post hoc analysis of data from a randomized, double‐blind multicenter study. J Am Heart Assoc. 2023;12:e027612.
Kusaka H, Sueta D, Koibuchi N, et al. LCZ696, Angiotensin II receptor‐neprilysin inhibitor, ameliorates high‐salt‐induced hypertension and cardiovascular injury more than valsartan alone. Am J Hypertens. 2015;28:1409‐1417.
Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT‐proBNP in salt‐sensitive hypertension. Hypertension. 2017;69:32‐41.
Sharma AM, Schorr U, Oelkers W, Distler A. Effects of sodium salts on plasma renin activity and norepinephrine response to orthostasis in salt‐sensitive normotensive subjects. Am J Hypertens. 1993;6:780‐785.
Umemura S, Arima H, Arima S, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235‐1481.
Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982‐992.
Li W, Gong M, Yu Q, et al. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension. J Clin Hypertens. 2022;24:449‐456.
Iwashima Y, Fukushima H, Horio T, Rai T, Ishimitsu T. Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension. J Clin Hypertens. 2023;25:304‐308.